Fed­er­al court gives Te­va and Vi­a­tris an­oth­er chance to in­val­i­date J&J's last patent for In­ve­ga Susten­na

John­son & John­son on­ly has one last patent cov­er­ing its long-act­ing block­buster schiz­o­phre­nia drug In­ve­ga Susten­na, and now Te­va and Vi­a­tris have an­oth­er op­por­tu­ni­ty to chal­lenge it fol­low­ing a fed­er­al cir­cuit pan­el de­ci­sion.

J&J’s Janssen unit (now J&J In­no­v­a­tive Med­i­cine) orig­i­nal­ly sued Te­va in 2018 over patent in­fringe­ment in the US Dis­trict Court of New Jer­sey in an at­tempt to pro­tect its ‘906 patent, which cov­ers the dos­ing reg­i­men. Te­va chal­lenged the va­lid­i­ty of the patent, but the court orig­i­nal­ly found that Te­va had not proven the patent was in­valid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER